Abstract
In this issue of Blood, Dickerson et al report on the increased incidence and worsening severity of hypertension and its association with cardiovascular outcomes in 562 patients treated with ibrutinib for B-cell malignancies.1
Cite
CITATION STYLE
APA
Ahn, I. E. (2019). Cardiovascular adverse events of ibrutinib. Blood. American Society of Hematology. https://doi.org/10.1182/blood.2019002805
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free